Journal of Osteoporosis / 2016 / Article / Tab 2

Research Article

Effect of Denosumab on Bone Mineral Density and Markers of Bone Turnover among Postmenopausal Women with Osteoporosis

Table 2

Bone markers in patients treated with Dmab (BP-naïve and BP-prior) and BP treated patients not switched to Dmab (control group).

Basal12 mChange (%)

BP-naïve
tAP (IU/L) 160.60 ± 16.32113.50 ± 11.28#↓29.33
BGP (ng/mL) 26.78 ± 3.15&20.22 ± 3.11#↓24.50
s-CTX (ng/L) 509.80 ± 54.66&101.40 ± 30.55#↓80.11

BP-prior
tAP (IU/L) 146.00 ± 010.21117.90 ± 8.32↓19.25
BGP (ng/mL) 19.58 ± 1.0610.53 ± 0.65↓46.22
s-CTX (ng/L) 314.90 ± 17.47101.20 ± 9.00↓67.86

Control group
tAP (IU/L) 147.90 ± 7.01141.30 ± 6.63ns
BGP (ng/mL) 17.37 ± 2.0016.08 ± 1.28ns
s-CTX (ng/L) 275.60 ± 28.67204.00 ± 17.05θ↓25.98%

Significant differences with BP-naïve basal; significant differences with BP-prior basal; significant differences with BP-prior basal; θsignificant differences with control group basal.

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.